Abstract 4897
Background
A noninvasive cfDNA test to detect early-stage pancreatic ductal adenocarcinoma (PDAC) is highly desirable to reduce PDAC’s high mortality rate. DNA methylation markers are promising to differentiate PDAC tissues from benign pancreas tissues, which may lead to liquid biopsy tests for PDAC early screening.
Methods
We have collected freshly frozen clinical PDAC tissues (N = 46), para-tumour pancreas tissues (N = 30), PDAC plasma samples (N = 120), chronical pancreatitis plasma samples (N = 90), and normal plasma samples (N = 100). Genomic DNA and circulating tumour DNA (ctDNA) samples were isolated and purified. DNA methylation profiles were generated by reduced representation bisulfite sequencing (RRBS). We quantified DNA methylation status of Methylation Haplotype Blocks (MHB) using Methylation Haplotype Load (MHL). Tumour-specific DNA methylation signatures were identified for PDAC by comparing MHL scores between PDAC and para-tumour pancreas tissues, PDAC tissues with normal cell-free circulating DNA (cfDNA), and PDAC ctDNA with normal cfDNA samples.
Results
We identified 350 of MHBs by combining unique MHBs identified in each comparison. Using MHB selected from tissue-vs-tissue comparison to build classifiers, we reiterated training and cross-validating PDAC tissue classification models using SVM method, and achieved the average sensitivity of 86% specificity of 88%, and AUC of 0.91. Other machine learning methods generated similar results. We further compared our markers with previously published DNA methylation markers for PDAC, and found that genes associated with published markers are highly enriched in the genes associated with our markers (p < 1E-20; hypergeometric test), indicating they may co-regulate a same set of genes that are involved in PDAC pathology. We have further developed NGS based panels and algorithms to classify PDAC patients using cell-free DNA (cfDNA) samples based on the identified methylation markers.
Conclusions
Using multiple metrics on MHBs, we identified PDAC-specific DNA methylation markers, some of which are functionally overlapped with previously reported markers. These markers are candidate biomarkers for non-invasive PDAC screening.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Peking Union Medical College Hospital and Singlera Genomics Inc.
Funding
China Science and Technology Exchange Center.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4732 - Progesterone Receptor Isoform Ratio Dictates Antiprogestins/Progestins Effects on Metastatic Breast Cancer Models
Presenter: Maria Abascal
Session: Poster Display session 2
Resources:
Abstract
5737 - PAM50 and CGH-array genomic characterization of HER2-Equivocal Breast Cancers defined by the 2018 ASCO/CAP recommendations.
Presenter: Carine Ngo
Session: Poster Display session 2
Resources:
Abstract
1096 - OncotypeDX® predictive nomogram for recurrence score output: a machine learning system based on quantitative immunochemistry analysis - ADAPTED01
Presenter: Fabio Marazzi
Session: Poster Display session 2
Resources:
Abstract
5426 - Geriatric parameters predict both disease-related and patient-reported outcomes in older patients with breast cancer
Presenter: Willeke van der Plas-Krijgsman
Session: Poster Display session 2
Resources:
Abstract
5865 - Patients with a 21-gene assay in South East London differ from the TAILORx trial population
Presenter: Charalampos Gousis
Session: Poster Display session 2
Resources:
Abstract
1312 - Predictive tools in adjuvant breast cancer – what is the standard of evidence supporting their utility? A literature review examining validation of Adjuvant!, Cancermath and NHS Predict
Presenter: Alice Loft
Session: Poster Display session 2
Resources:
Abstract
2445 - Oncologic outcome of invasive lobular carcinoma: Is it different from that of invasive ductal carcinoma?
Presenter: Hee Jun Choi
Session: Poster Display session 2
Resources:
Abstract
2476 - Pathologic response and survival efficacy in patients with initial nodal involvement after neoadjuvant chemotherapy in early breast cancer
Presenter: SERAFIN MORALES Murillo
Session: Poster Display session 2
Resources:
Abstract
3761 - Chemotherapy-induced amenorrhea: prognostic impact on premenopausal Egyptian patients with breast cancer
Presenter: Khaled Abdel Karim
Session: Poster Display session 2
Resources:
Abstract
4687 - Predicting the presence of breast cancer using circulating small RNA in the serum
Presenter: Yumiko Koi
Session: Poster Display session 2
Resources:
Abstract